Question special
Consultants/ Senior Lecturer

Dear Authors, We really enjoyed reading and discussing your paper in our journal club. One thing we noted was that your trial was being conducted at a time when concerns were emerging about another Dengue vaccine, Dengvaxia, causing an increased risk of severe Dengue in individuals who were seronegative at the time of vaccination. Did this impact on your ability to recruit to the trial, or result in any concerns from participants after they had been vaccinated? If so, how did you deal with this? It seems you had 4 recruitment sites in the Philippines, but only 12.4% of subjects were recruited there. Is that a reflection of particularly strong concerns in the Philippines?